FDA Grants Orphan Designation To CycloSam For Treatment of Osteosarcoma

Release Date: 28-Sep-2021

US FDA has granted Orphan Drug Designation of CycloSamandreg; for the treatment of patients diagnosed with osteosarcoma. CycloSam drug candidate utilizes both a more efficient method of isotope manufacturing and an advanced chelation technology which may potentially allow for repeated dosing of patients with bone cancer in an effort to halt or reverse tumor growth.


Osteosarcoma is the most common form of bone cancer in children and young adults (ages 15-39) with primary high-grade bone malignancy. Out of 5 patients only 1 will survive who develop or present with metastatic osteosarcoma bone cancer.

Need custom market research solution? We can help you with that too.